Description: We use mass spectrometry-based peptidomics and proteomics for the identification and validation of novel biomarker candidates and to study mechanisms of neurodegenerative diseases in translational research projects and clinical samples.
mass spectrometry (140) proteomics (110) biomarker (44) neurodegenerative disease (7) peptidomics (2)
Translational Mass Spectrometry and Biomarker Research PD Dr. Patrick Öckl Research Overview Research Areas Research Groups Studies Probandeninformation Brain Bank Projects Scientific Services Publications News Overview Donations About us Übersicht Organization Sites Prizes and Awards Technology Transfer Collaborations Works Council Career Home Research Research areas Fundamental Research Research Groups Öckl Research areas/focus Curriculum vitae Research areas/focus Group members Publications Curriculum vi
Diagnosis of neurodegenerative diseases and monitoring of disease progression is mainly based on clinical symptoms. This is hampered by the symptomatic overlap between some neurodegenerative diseases bearing the risk of misdiagnosis. In addition, early diagnosis in the asymptomatic stage is impossible.
A biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention (National Institutes of Health, NIH)”. It can help to improve differential and early diagnosis and monitor and predict disease progression. Biomarkers are also essential for the evaluation of treatment effects in clinical trials. The measurement of biomarkers in biological fluids such as blood or cerebrospin